Skip to main content
Erschienen in: Current Dermatology Reports 1/2018

03.02.2018 | Skin Cancer (D Siegel and O Markowitz, Section Editors)

Update on Noninvasive Diagnostic Imaging and Management of Nonmelanoma Skin Cancer

verfasst von: Amanda Levine, Daniel M. Siegel, Orit Markowitz

Erschienen in: Current Dermatology Reports | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The focus of this review is to present some of the new noninvasive diagnostic imaging tools and their use in conjunction with nonsurgical modalities that have been demonstrated to be effective for the treatment and prevention of nonmelanoma skin cancer (NMSC).

Recent Findings

Given the vast prevalence of NMSC and substantial associated morbidity, clinicians are working toward effective nonsurgical therapeutic options, including topical treatments, laser and photodynamic therapy, radiation as well as newer systemic treatment modalities. With this shift toward increasingly nonsurgical therapies comes the need to find new noninvasive ways to assess treatment efficacy, monitor treatment response, and detect subclinical residual disease.

Summary

Recent developments in imaging modalities, including dermoscopy, optical coherence tomography, and reflectance confocal microscopy, are emerging as useful tools for diagnosis and treatment management of NMSC.
Literatur
5.
Zurück zum Zitat Ulrich M, Von Braunmuehl T, Kurzen H, Dirschka T, Kellner C, Sattler E, et al. The sensitivity and specificity of optical coherence tomography for the assisted diagnosis of nonpigmented basal cell carcinoma: an observational study. Br J Dermatol. 2015;173(2):428–35. https://doi.org/10.1111/bjd.13853.PubMedCrossRef Ulrich M, Von Braunmuehl T, Kurzen H, Dirschka T, Kellner C, Sattler E, et al. The sensitivity and specificity of optical coherence tomography for the assisted diagnosis of nonpigmented basal cell carcinoma: an observational study. Br J Dermatol. 2015;173(2):428–35. https://​doi.​org/​10.​1111/​bjd.​13853.PubMedCrossRef
6.
Zurück zum Zitat Markowitz O, Schwartz M, Feldman E, et al. Evaluation of Optical Coherence Tomography as a Means of Identifying Earlier Stag ... Page 1 sur 7 Evaluation of Optical Coherence Tomography as a Means of Identifying Earlier Stage Basal Cell Carcinomas while Reducing the Use of Diagnostic Biopsy. J Clin Aesthet Dermatol. 2015;8:14–20.PubMedPubMedCentral Markowitz O, Schwartz M, Feldman E, et al. Evaluation of Optical Coherence Tomography as a Means of Identifying Earlier Stag ... Page 1 sur 7 Evaluation of Optical Coherence Tomography as a Means of Identifying Earlier Stage Basal Cell Carcinomas while Reducing the Use of Diagnostic Biopsy. J Clin Aesthet Dermatol. 2015;8:14–20.PubMedPubMedCentral
9.
Zurück zum Zitat Gambichler T, Schmid-Wendtner MH, Plura I, Kampilafkos P, Stücker M, Berking C, et al. A multicentre pilot study investigating high-definition optical coherence tomography in the differentiation of cutaneous melanoma and melanocytic naevi. J Eur Acad Dermatol Venereol. 2015;29(3):537–41. https://doi.org/10.1111/jdv.12621.PubMedCrossRef Gambichler T, Schmid-Wendtner MH, Plura I, Kampilafkos P, Stücker M, Berking C, et al. A multicentre pilot study investigating high-definition optical coherence tomography in the differentiation of cutaneous melanoma and melanocytic naevi. J Eur Acad Dermatol Venereol. 2015;29(3):537–41. https://​doi.​org/​10.​1111/​jdv.​12621.PubMedCrossRef
10.
Zurück zum Zitat Boone MALM, Suppa M, Dhaenens F, Miyamoto M, Marneffe A, Jemec GBE, et al. In vivo assessment of optical properties of melanocytic skin lesions and differentiation of melanoma from non-malignant lesions by high-definition optical coherence tomography. Arch Dermatol Res. 2016;308(1):7–20. https://doi.org/10.1007/s00403-015-1608-5.PubMedCrossRef Boone MALM, Suppa M, Dhaenens F, Miyamoto M, Marneffe A, Jemec GBE, et al. In vivo assessment of optical properties of melanocytic skin lesions and differentiation of melanoma from non-malignant lesions by high-definition optical coherence tomography. Arch Dermatol Res. 2016;308(1):7–20. https://​doi.​org/​10.​1007/​s00403-015-1608-5.PubMedCrossRef
11.
Zurück zum Zitat Marneffe A, Suppa M, Miyamoto M, Del Marmol V, Boone M. Validation of a diagnostic algorithm for the discrimination of actinic keratosis from normal skin and squamous cell carcinoma by means of high-definition optical coherence tomography. Exp Dermatol. 2016;25(9):684–7. https://doi.org/10.1111/exd.13036.PubMedCrossRef Marneffe A, Suppa M, Miyamoto M, Del Marmol V, Boone M. Validation of a diagnostic algorithm for the discrimination of actinic keratosis from normal skin and squamous cell carcinoma by means of high-definition optical coherence tomography. Exp Dermatol. 2016;25(9):684–7. https://​doi.​org/​10.​1111/​exd.​13036.PubMedCrossRef
13.
Zurück zum Zitat Levine A, Markowitz O. vivo reflectance confocal microscopy. Cutis. 2017;99(6):399–402.PubMed Levine A, Markowitz O. vivo reflectance confocal microscopy. Cutis. 2017;99(6):399–402.PubMed
14•.
17.
Zurück zum Zitat Malvehy J, Alarcon I, Montoya J, Rodríguez-Azeredo R, Puig S. Treatment monitoring of 0.5% 5-fluorouracil and 10% salicylic acid in clinical and subclinical actinic keratoses with the combination of optical coherence tomography and reflectance confocal microscopy. J Eur Acad Dermatol Venereol. 2016;30(2):258–65. https://doi.org/10.1111/jdv.13445.PubMedCrossRef Malvehy J, Alarcon I, Montoya J, Rodríguez-Azeredo R, Puig S. Treatment monitoring of 0.5% 5-fluorouracil and 10% salicylic acid in clinical and subclinical actinic keratoses with the combination of optical coherence tomography and reflectance confocal microscopy. J Eur Acad Dermatol Venereol. 2016;30(2):258–65. https://​doi.​org/​10.​1111/​jdv.​13445.PubMedCrossRef
18.
Zurück zum Zitat Lanoue J, Goldenberg G. Basal cell carcinoma—a comprehensive review of existing and emerging nonsurgical therapies. J Clin Aesthetic Dermatol. 2016;9:26–36. Lanoue J, Goldenberg G. Basal cell carcinoma—a comprehensive review of existing and emerging nonsurgical therapies. J Clin Aesthetic Dermatol. 2016;9:26–36.
27.
Zurück zum Zitat Quirk C, Gebauer K, De’Ambrosis B, Slade HB, Meng TC. Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study. Cutis. 2010;85(6):318–24.PubMed Quirk C, Gebauer K, De’Ambrosis B, Slade HB, Meng TC. Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study. Cutis. 2010;85(6):318–24.PubMed
28.
Zurück zum Zitat Gollnick H, Barona CG, Frank RG, Ruzicka T, Megahed M, Maus J, et al. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. Eur J Dermatol. 2008;18(6):677–82. https://doi.org/10.1684/ejd.2008.0519. PubMed Gollnick H, Barona CG, Frank RG, Ruzicka T, Megahed M, Maus J, et al. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. Eur J Dermatol. 2008;18(6):677–82. https://​doi.​org/​10.​1684/​ejd.​2008.​0519.​ PubMed
30•.
Zurück zum Zitat Williams HC, Bath-Hextall F, Ozolins M, Armstrong SJ, Colver GB, Perkins W, et al. Surgery versus 5% imiquimod for nodular and superficial basal cell carcinoma: 5-year results of the SINS randomized controlled trial. J Invest Dermatol. 2017;137(3):614–9. https://doi.org/10.1016/j.jid.2016.10.019. This research reports 5-year benefit for topical imiquimod compared with surgery for superficial or nodular basal cell carcinoma. PubMedCrossRef Williams HC, Bath-Hextall F, Ozolins M, Armstrong SJ, Colver GB, Perkins W, et al. Surgery versus 5% imiquimod for nodular and superficial basal cell carcinoma: 5-year results of the SINS randomized controlled trial. J Invest Dermatol. 2017;137(3):614–9. https://​doi.​org/​10.​1016/​j.​jid.​2016.​10.​019. This research reports 5-year benefit for topical imiquimod compared with surgery for superficial or nodular basal cell carcinoma. PubMedCrossRef
33.
Zurück zum Zitat Swanson N, Smith CC, Kaur M, Goldenberg G. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double-blind, placebo-controlled studies. J Drugs Dermatol. 2014;13(2):166–9.PubMed Swanson N, Smith CC, Kaur M, Goldenberg G. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double-blind, placebo-controlled studies. J Drugs Dermatol. 2014;13(2):166–9.PubMed
37.
Zurück zum Zitat Apalla Z, Lallas A, Tzellos T, Sidiropoulos T, Lefaki I, Trakatelli M, et al. Applicability of dermoscopy for evaluation of patients’ response to nonablative therapies for the treatment of superficial basal cell carcinoma. Br J Dermatol. 2014;170(4):809–15. https://doi.org/10.1111/bjd.12749.PubMedCrossRef Apalla Z, Lallas A, Tzellos T, Sidiropoulos T, Lefaki I, Trakatelli M, et al. Applicability of dermoscopy for evaluation of patients’ response to nonablative therapies for the treatment of superficial basal cell carcinoma. Br J Dermatol. 2014;170(4):809–15. https://​doi.​org/​10.​1111/​bjd.​12749.PubMedCrossRef
43.
45.
Zurück zum Zitat Weiss J, Menter A, Hevia O, Jones T, Ling M, Rist T, et al. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis. 2002;70(2 Suppl):22–9.PubMed Weiss J, Menter A, Hevia O, Jones T, Ling M, Rist T, et al. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis. 2002;70(2 Suppl):22–9.PubMed
48.
Zurück zum Zitat Jorizzo JL, Carney PS, Ko WT, Robins P, Weinkle SH, Werschler WP. Fluorouracil 5% and 0.5% creams for the treatment of actinic keratosis: equivalent efficacy with a lower concentration and more convenient dosing schedule. Cutis. 2004;74(6 Suppl):18–23.PubMed Jorizzo JL, Carney PS, Ko WT, Robins P, Weinkle SH, Werschler WP. Fluorouracil 5% and 0.5% creams for the treatment of actinic keratosis: equivalent efficacy with a lower concentration and more convenient dosing schedule. Cutis. 2004;74(6 Suppl):18–23.PubMed
50.
Zurück zum Zitat Simon JC, Dominicus R, Karl L, Rodríguez R, Willers C, Dirschka T. A prospective randomized exploratory study comparing the efficacy of once-daily topical 0.5% 5-fluorouracil in combination with 10.0% salicylic acid (5-FU/SA) vs. cryosurgery for the treatment of hyperkeratotic actinic keratosis. J Eur Acad Dermatol Venereol. 2015;29(5):881–9. https://doi.org/10.1111/jdv.12702.PubMedCrossRef Simon JC, Dominicus R, Karl L, Rodríguez R, Willers C, Dirschka T. A prospective randomized exploratory study comparing the efficacy of once-daily topical 0.5% 5-fluorouracil in combination with 10.0% salicylic acid (5-FU/SA) vs. cryosurgery for the treatment of hyperkeratotic actinic keratosis. J Eur Acad Dermatol Venereol. 2015;29(5):881–9. https://​doi.​org/​10.​1111/​jdv.​12702.PubMedCrossRef
52.
Zurück zum Zitat Ulrich M, Reinhold U, Falqués M, Rodriguez Azeredo R, Stockfleth E. Use of reflectance confocal microscopy to evaluate 5-fluorouracil 0.5% /salicylic acid 10% in the field-directed treatment of sub-clinical lesions of actinic keratosis: sub-analysis of a phase III, randomised, double-blind, vehicle-controlled trial. J Eur Acad Dermatol Venereol. 2017; https://doi.org/10.1111/jdv.14611. Ulrich M, Reinhold U, Falqués M, Rodriguez Azeredo R, Stockfleth E. Use of reflectance confocal microscopy to evaluate 5-fluorouracil 0.5% /salicylic acid 10% in the field-directed treatment of sub-clinical lesions of actinic keratosis: sub-analysis of a phase III, randomised, double-blind, vehicle-controlled trial. J Eur Acad Dermatol Venereol. 2017; https://​doi.​org/​10.​1111/​jdv.​14611.
54.
59.
Zurück zum Zitat Maier T, Cekovic D, Ruzicka T, Sattler EC, Berking C. Treatment monitoring of topical ingenol mebutate in actinic keratoses with the combination of optical coherence tomography and reflectance confocal microscopy: a case series. Br J Dermatol. 2015;172(3):816–8. https://doi.org/10.1111/bjd.13304.PubMedCrossRef Maier T, Cekovic D, Ruzicka T, Sattler EC, Berking C. Treatment monitoring of topical ingenol mebutate in actinic keratoses with the combination of optical coherence tomography and reflectance confocal microscopy: a case series. Br J Dermatol. 2015;172(3):816–8. https://​doi.​org/​10.​1111/​bjd.​13304.PubMedCrossRef
60.
Zurück zum Zitat Ulrich M, Lange-Asschenfeldt S, Skak K, Skov T, Osterdal M, Rowert-Huber H, et al. Biological effects of ingenol mebutate gel in moderate to severe actinic fields assessed by reflectance confocal microscopy: a phase I study. J Drugs Dermatol. 2016;15(10):1181–9.PubMed Ulrich M, Lange-Asschenfeldt S, Skak K, Skov T, Osterdal M, Rowert-Huber H, et al. Biological effects of ingenol mebutate gel in moderate to severe actinic fields assessed by reflectance confocal microscopy: a phase I study. J Drugs Dermatol. 2016;15(10):1181–9.PubMed
61.
Zurück zum Zitat Markowitz O, Schwartz M, Feldman E, Bieber AMY, Bienenfeld A, Nandanan N, et al. Defining field cancerization of the skin using noninvasive optical coherence tomography imaging to detect and monitor actinic. J Clin Aesthet Dermatol. 2016;9:18–26.PubMedPubMedCentral Markowitz O, Schwartz M, Feldman E, Bieber AMY, Bienenfeld A, Nandanan N, et al. Defining field cancerization of the skin using noninvasive optical coherence tomography imaging to detect and monitor actinic. J Clin Aesthet Dermatol. 2016;9:18–26.PubMedPubMedCentral
66.
Zurück zum Zitat Morton CA, Szeimies RM, Sidoroff A, Braathen LR. European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications-actinic keratoses, Bowen’s disease, basal cell carcinoma. J Eur Acad Dermatol Venereol. 2013;27(5):536–44. https://doi.org/10.1111/jdv.12031.PubMedCrossRef Morton CA, Szeimies RM, Sidoroff A, Braathen LR. European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications-actinic keratoses, Bowen’s disease, basal cell carcinoma. J Eur Acad Dermatol Venereol. 2013;27(5):536–44. https://​doi.​org/​10.​1111/​jdv.​12031.PubMedCrossRef
69.
Zurück zum Zitat Reinhold U, Dirschka T, Ostendorf R, Aschoff R, Berking C, Philipp-Dormston WG, et al. A randomized, double-blind, phase III, multicentre study to evaluate the safety and efficacy of BF-200 ALA (Ameluz(®) ) vs. placebo in the field-directed treatment of mild-to-moderate actinic keratosis with photodynamic therapy (PDT) when using the BF-Rho. Br J Dermatol. 2016;175(4):696–705. https://doi.org/10.1111/bjd.14498. PubMedCrossRef Reinhold U, Dirschka T, Ostendorf R, Aschoff R, Berking C, Philipp-Dormston WG, et al. A randomized, double-blind, phase III, multicentre study to evaluate the safety and efficacy of BF-200 ALA (Ameluz(®) ) vs. placebo in the field-directed treatment of mild-to-moderate actinic keratosis with photodynamic therapy (PDT) when using the BF-Rho. Br J Dermatol. 2016;175(4):696–705. https://​doi.​org/​10.​1111/​bjd.​14498.​ PubMedCrossRef
72.
Zurück zum Zitat Warren CB, Lohser S, Wene LC, Pogue BW, Bailin PL, Maytin EV. Noninvasive fluorescence monitoring of protoporphyrin IX production and clinical outcomes in actinic keratoses following short-contact application of 5-aminolevulinate. J Biomed Opt. 2015;15:51607. https://doi.org/10.1117/1.3484255. CrossRef Warren CB, Lohser S, Wene LC, Pogue BW, Bailin PL, Maytin EV. Noninvasive fluorescence monitoring of protoporphyrin IX production and clinical outcomes in actinic keratoses following short-contact application of 5-aminolevulinate. J Biomed Opt. 2015;15:51607. https://​doi.​org/​10.​1117/​1.​3484255.​ CrossRef
79.
83.
Zurück zum Zitat De Vijlder HC, Sterenborg HJCM, Martino Neumann HA, Robinson DJ, De Haas ERM. Light fractionation significantly improves the response of superficial basal cell carcinoma to aminolaevulinic acid photodynamic therapy: five-year follow-up of a randomized, prospective trial. Acta Derm Venereol. 2012;92(6):641–7. https://doi.org/10.2340/00015555-1448.PubMedCrossRef De Vijlder HC, Sterenborg HJCM, Martino Neumann HA, Robinson DJ, De Haas ERM. Light fractionation significantly improves the response of superficial basal cell carcinoma to aminolaevulinic acid photodynamic therapy: five-year follow-up of a randomized, prospective trial. Acta Derm Venereol. 2012;92(6):641–7. https://​doi.​org/​10.​2340/​00015555-1448.PubMedCrossRef
88.
Zurück zum Zitat Venturini M, Sala R, Gonzàlez S, Calzavara-Pinton PG. Reflectance confocal microscopy allows in vivo real-time noninvasive assessment of the outcome of methyl aminolaevulinate photodynamic therapy of basal cell carcinoma. Br J Dermatol. 2013;168(1):99–105. https://doi.org/10.1111/bjd.12052.PubMedCrossRef Venturini M, Sala R, Gonzàlez S, Calzavara-Pinton PG. Reflectance confocal microscopy allows in vivo real-time noninvasive assessment of the outcome of methyl aminolaevulinate photodynamic therapy of basal cell carcinoma. Br J Dermatol. 2013;168(1):99–105. https://​doi.​org/​10.​1111/​bjd.​12052.PubMedCrossRef
100.
104•.
Zurück zum Zitat Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17(1):332. https://doi.org/10.1186/s12885-017-3286-5. This research article reports long-term safety and final investigator-assessed efficacy results in patients with metastatic or locally advanced basal cell carcinoma treated with vismodegib. PubMedPubMedCentralCrossRef Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17(1):332. https://​doi.​org/​10.​1186/​s12885-017-3286-5. This research article reports long-term safety and final investigator-assessed efficacy results in patients with metastatic or locally advanced basal cell carcinoma treated with vismodegib. PubMedPubMedCentralCrossRef
108.
109•.
Zurück zum Zitat Lear JT, Migden MR, Lewis KD, Chang ALS, Guminski A, Gutzmer R, et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol. 2017;38:42–9. https://doi.org/10.1111/jdv.14542. This research article reports long-term safety and efficacy of sonidegib in locally advanced and metastatic basal cell carcinoma at 18- and 30- month analyses. Lear JT, Migden MR, Lewis KD, Chang ALS, Guminski A, Gutzmer R, et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol. 2017;38:42–9. https://​doi.​org/​10.​1111/​jdv.​14542. This research article reports long-term safety and efficacy of sonidegib in locally advanced and metastatic basal cell carcinoma at 18- and 30- month analyses.
111.
114.
Zurück zum Zitat Markowitz O, Schwartz M. The use of noninvasive optical coherence tomography to monitor the treatment progress of vismodegib and imiquimod 5% cream in a transplant patient with advanced basal cell carcinoma of the nose. J Clin Aesthet Dermatol. 2016;9(8):37–41.PubMedPubMedCentral Markowitz O, Schwartz M. The use of noninvasive optical coherence tomography to monitor the treatment progress of vismodegib and imiquimod 5% cream in a transplant patient with advanced basal cell carcinoma of the nose. J Clin Aesthet Dermatol. 2016;9(8):37–41.PubMedPubMedCentral
119.
Zurück zum Zitat McGregor S, Minni J. Superficial radiation therapy for the treatment of nonmelanoma skin cancers. Am Heart J. 1973;85:563–8.CrossRef McGregor S, Minni J. Superficial radiation therapy for the treatment of nonmelanoma skin cancers. Am Heart J. 1973;85:563–8.CrossRef
Metadaten
Titel
Update on Noninvasive Diagnostic Imaging and Management of Nonmelanoma Skin Cancer
verfasst von
Amanda Levine
Daniel M. Siegel
Orit Markowitz
Publikationsdatum
03.02.2018
Verlag
Springer US
Erschienen in
Current Dermatology Reports / Ausgabe 1/2018
Elektronische ISSN: 2162-4933
DOI
https://doi.org/10.1007/s13671-018-0207-z

Weitere Artikel der Ausgabe 1/2018

Current Dermatology Reports 1/2018 Zur Ausgabe

Itch (E. Lerner, Section Editor)

Evaluation of the Itchy Patient

Psoriasis (Jaishin Wu, Section Editor)

Update on Oral Therapy for Psoriasis

Psoriasis (Jaishin Wu, Section Editor)

Review Update on Topical Therapy for Psoriasis

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.